<?xml version='1.0' encoding='utf-8'?>
<document id="19914261"><sentence text="Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes."><entity charOffset="15-29" id="DDI-PubMed.19914261.s1.e0" text="angiotensin II" /></sentence><sentence text="The inhibitory effect of angiotensin II type 1 receptor blockers (ARBs) on P-glycoprotein (P-gp) was examined to evaluate their clinical drug-drug interaction (DDI) potential"><entity charOffset="25-39" id="DDI-PubMed.19914261.s2.e0" text="angiotensin II" /></sentence><sentence text="" /><sentence text="We performed an inhibition study on the vectorial transport of digoxin, a typical substrate for P-gp, using a human colonic adenocarcinoma cell line, Caco-2 cells, and verapamil-stimulated ATPase activity using human multidrug resistance 1 (hMDR1)-expressing membrane"><entity charOffset="63-70" id="DDI-PubMed.19914261.s4.e0" text="digoxin" /></sentence><sentence text="" /><sentence text="The vectorial transport of digoxin was inhibited by candesartan cilexetil, irbesartan and telmisartan with the IC(50) values of 14"><entity charOffset="27-34" id="DDI-PubMed.19914261.s6.e0" text="digoxin" /><entity charOffset="75-85" id="DDI-PubMed.19914261.s6.e1" text="irbesartan" /><entity charOffset="90-101" id="DDI-PubMed.19914261.s6.e2" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.19914261.s6.e0" e2="DDI-PubMed.19914261.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19914261.s6.e0" e2="DDI-PubMed.19914261.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19914261.s6.e0" e2="DDI-PubMed.19914261.s6.e2" /><pair ddi="false" e1="DDI-PubMed.19914261.s6.e1" e2="DDI-PubMed.19914261.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19914261.s6.e1" e2="DDI-PubMed.19914261.s6.e2" /></sentence><sentence text="7, 34" /><sentence text="0 and 2" /><sentence text="19microM, respectively" /><sentence text=" Those values were 7" /><sentence text="4-426-fold higher than their theoretical clinical gastrointestinal concentration [I] at doses in clinical DDI studies" /><sentence text=" Other ARBs failed to show interaction with P-gp" /><sentence text="" /><sentence text="It was demonstrated that candesartan cilexetil, irbesartan and telmisartan had the potential to inhibit the transport of various drugs via P-gp"><entity charOffset="25-46" id="DDI-PubMed.19914261.s14.e0" text="candesartan cilexetil" /><entity charOffset="48-58" id="DDI-PubMed.19914261.s14.e1" text="irbesartan" /><entity charOffset="63-74" id="DDI-PubMed.19914261.s14.e2" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.19914261.s14.e0" e2="DDI-PubMed.19914261.s14.e0" /><pair ddi="false" e1="DDI-PubMed.19914261.s14.e0" e2="DDI-PubMed.19914261.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19914261.s14.e0" e2="DDI-PubMed.19914261.s14.e2" /><pair ddi="false" e1="DDI-PubMed.19914261.s14.e1" e2="DDI-PubMed.19914261.s14.e1" /><pair ddi="false" e1="DDI-PubMed.19914261.s14.e1" e2="DDI-PubMed.19914261.s14.e2" /></sentence><sentence text=" Telmisartan, which caused an increase in the serum digoxin concentration in humans, had a sufficiently high [I]/IC(50) value, suggesting that DDI between digoxin and telmisartan was caused by the inhibition of digoxin efflux via intestinal P-gp"><entity charOffset="1-12" id="DDI-PubMed.19914261.s15.e0" text="Telmisartan" /><entity charOffset="52-59" id="DDI-PubMed.19914261.s15.e1" text="digoxin" /><entity charOffset="155-162" id="DDI-PubMed.19914261.s15.e2" text="digoxin" /><entity charOffset="167-178" id="DDI-PubMed.19914261.s15.e3" text="telmisartan" /><entity charOffset="211-218" id="DDI-PubMed.19914261.s15.e4" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e0" e2="DDI-PubMed.19914261.s15.e0" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e0" e2="DDI-PubMed.19914261.s15.e1" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e0" e2="DDI-PubMed.19914261.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e0" e2="DDI-PubMed.19914261.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e0" e2="DDI-PubMed.19914261.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e1" e2="DDI-PubMed.19914261.s15.e1" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e1" e2="DDI-PubMed.19914261.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e1" e2="DDI-PubMed.19914261.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e1" e2="DDI-PubMed.19914261.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e2" e2="DDI-PubMed.19914261.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e2" e2="DDI-PubMed.19914261.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e2" e2="DDI-PubMed.19914261.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e3" e2="DDI-PubMed.19914261.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19914261.s15.e3" e2="DDI-PubMed.19914261.s15.e4" /></sentence><sentence text="" /></document>